NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company
will present data from its Phase 2 trial of PTG-300 for the
treatment of beta-thalassemia at the 25th European
Hematology Association (EHA) Annual Congress, which will take place
in a virtual format June 11-14, 2020.
Details of the oral presentation are as follows:
Presentation Title: A hepcidin mimetic, PTG-300, demonstrates
pharmacodynamic effects indicating reduced iron availability in
transfusion-dependent beta-thalassemia subjects
Session: New therapeutic approaches for thalassemia
Date and Time: Available on the on-demand Virtual Congress platform
on Friday, June 12, 2020, at
8:30 a.m. CEST
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. The Company currently has three clinical-stage assets.
PTG-300 is an injectable hepcidin mimetic in development for the
treatment of polycythemia vera and hereditary hemochromatosis.
PTG-200 is an orally delivered, gut-restricted, interleukin-23
receptor specific antagonist peptide in development for the
treatment of inflammatory bowel disease, with Crohn's disease as
the initial indication. The Company has a worldwide license and
collaboration agreement with Janssen Biotech, Inc., for the
development of PTG-200. PN-943 is an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
in development for the treatment of inflammatory bowel disease,
with ulcerative colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original content to download
SOURCE Protagonist Therapeutics, Inc.